Harvard Apparatus Regenerative Technology EBIT

The latest EBIT for HRGN is $-6.7M as of June 2026. That compares with $-6.7M in the prior-year period — up 1.0% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Harvard Apparatus Regenerative Technology's historical trend and sector peers before judging valuation or financial health.

Over the past year, HRGN's EBIT moved from $-6.7M to $-6.7M — a 1.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Harvard Apparatus Regenerative Technology's operating scale or balance-sheet position.

Against Healthcare companies, HRGN currently prints $-6.7M for EBIT, while the sector average sits near $22B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Harvard Apparatus Regenerative Technology's growth, margins, and balance sheet.

A EBIT figure of $-6.7M for HRGN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting HRGN's EBIT ($-6.7M), review year-over-year change from $-6.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.